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Abstract
Bcl-2 is commonly overexpressed in tumors, where it is often associated with unfavorable outcome. However, it
has also been linked to a favorable sensitivity to microtubule-targeting agents (MTAs). We show that Bcl-2–
overexpressing lung and breast cancer cells were more sensitive to both paclitaxel and vinorelbine. Bcl-2 over-
expression also significantly potentiated in vivo efficacy of paclitaxel, in terms of tumor volume decrease and
survival benefits, in models of nude mice bearing lung cancer xenografts. To further investigate this favorable
effect of Bcl-2, a genomic approach was taken. It revealed that Bcl-2 overexpression induced up-regulation of
the proapoptotic protein Bim in lung cancer cells and that, conversely, Bcl-2 silencing decreased Bim expression
level. A gene regulation study implicated the transcription factor Forkhead box-containing protein, class O3a in Bim
up-regulation. Lastly, we show that Bim was responsible for MTA-triggered lung cancer cell death through a
dynamin-related protein 1–mediated mitochondrial fragmentation. The Bcl-2–governed Bim induction evidence
offers for the first time an explanation for the favorable higher sensitivity to treatment shown by Bcl-2–overexpressing
cells. We suggest that Bim could be a powerful predictive factor for tumor response to MTA chemotherapy. Our data
also give new insight into some failures in the efficacy of therapies targeted against Bcl-2.
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Introduction
Microtubule-targeting agents (MTAs) are known to inhibit cancer
expansion through both antitumor and antiangiogenic properties.
This therapeutic class is used to treat a broad range of solid tumors,
including neuroblastoma and lung and breast cancers. It is well known
that MTAs commonly disturb dynamics of the microtubule plus ends
[1,2] and induce cell death through the mitochondrial apoptotic path-
way [3,4]. Whether a cell survives or dies through apoptosis is deter-
mined by the relative levels of Bcl-2 family proteins. The antiapoptotic
members, such as Bcl-2, secure mitochondrial integrity, whereas the
proapoptotic members, such as Bim, facilitate the release of apopto-
genic factors from the intermembrane space of mitochondria to cytosol
[5]. In MTA-treated cells, the mitochondrial network undergoes very
marked morphologic changes, from long tubular to short punctiform
structures [3]. This fragmentation may contribute to mitochondrial
injury and release of apoptogenic factors in the cytosol [6,7]. The
dynamin-related protein 1 (Drp1) is crucial for fission [8,9], but grow-
ing evidence suggests that members of the Bcl-2 family may also be
involved in the regulation of the mitochondrial network organization
[10,11].
Overexpression of Bcl-2 is commonly found in various types of
cancer and is generally regarded as a biomarker of resistance to both
radiotherapy and chemotherapy [12–14]. Accordingly, targeted
therapies directed to Bcl-2, such as the Bcl-2 antisense oligodeoxy-
nucleotide oblimersen, are now available for phase I to III clinical
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trials [15]. However, these therapies have produced inconsistent
results. For example, addition of oblimersen to carboplatin and eto-
poside did not improve clinical outcome measured in patients with
small cell lung cancers [16]. Recent studies in breast and prostate
cancers also concluded that the combination of oblimersen with doce-
taxel did not display any efficacy [17,18].
These discrepant results must be reanalyzed in the light of the
controversial role of Bcl-2 in its resistance to anticancer drugs. Bcl-2
overexpression paradoxically enhanced in vitro sensitivity to docetaxel
in non–small cell lung cancer [19] and to vinca alkaloids in breast
cancer cells [20]. Consistent with this finding, low Bcl-2 expression
levels were responsible for ovarian cancer cell resistance to paclitaxel
and vinflunine, while reintroducing Bcl-2 restored cell sensitivity to
treatment [21,22]. All these data support an equivocal role for Bcl-2
in the mechanism of action of MTAs. Conversely, there is no doubt
about the involvement of Bim in MTA-induced apoptosis [23–25].
In healthy cells, Bim can bind to LC8 and is thereby sequestered to
the microtubule-associated dynein motor complex [26]. In a previous
study, we showed that MTA treatment caused Bim translocation to
mitochondria to trigger neuroblastoma cell death. Studies that aim at
deciphering the molecular mechanisms underlying Bim activation
during MTA-induced apoptosis have revealed an important role for
the transcriptional regulation of bim gene expression [27]. Bim tran-
scription is mainly controlled by transcription factors of the Forkhead
box-containing protein, class O (FoxO) family, which are inhibited by
phosphorylation through phosphatidylinositol 3 kinase (PI3K), AKT,
and serum and glucocorticoid-inducible kinases (SGKs) [28,29].
The aim of this study was to decipher the role of Bcl-2 in human
cancer cell sensitivity or resistance to MTAs. The study design, using
bcl-2 gene transfer in tumor cell lines of different origins (lung,
breast, and neuroblastoma), enables us to efficiently induce Bcl-2
overexpression, as observed in many patients [30–32]. This study
may help us determine the best treatment for tumors that intrinsi-
cally overexpress Bcl-2 and so improve the outcome of these patients.
First, we found that Bcl-2 overexpression selectively increased efficacy
of paclitaxel and vinorelbine in lung and breast carcinoma cells. This
finding was validated in nude mice bearing non–small cell lung cancer
xenografts, where Bcl-2 overexpression potentiated in vivo paclitaxel
efficacy. A genomic approach then showed that Bcl-2 overexpression
was responsible for a significant increase in bim expression levels. We
also found that Bim up-regulation was mediated by FoxO3a activation.
Lastly, we show that Bim involvement in cell sensitivity to treatment
relies on its ability to trigger the mitochondrial network fragmentation.
We thus offer, for the first time, an explanation for the higher sensitivity
toMTAs displayed byBcl-2–overexpressing cancer cells. Taken together,
our data strongly suggest that Bim could serve as a biomarker of choice
in predicting treatment efficacy.
Materials and Methods
Cell Lines and Reagents
Human non–small cell lung carcinoma (A549), neuroblastoma
(SHEP), and breast cancer (MCF-7) cells were purchased from
ATCC (Molsheim, France). These three lines were transfected using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA) with an empty plasmid
pUse (Upstate Biotechnology, Lake Placid, NY) for control cells (A549
pUse, SHEP pUse, or MCF-7 pUse) or with a plasmid containing
human Bcl-2 cDNA (pUse Bcl-2 vector) kindly given by Ferlini [21].
Various stable transfectants were obtained after geneticin selection
(A549 Bcl-2, SHEP Bcl-2, andMCF-7 Bcl-2). All these lines were rou-
tinely cultured in RPMI supplemented with 10% FBS, 2% L-glutamine,
and 1% penicillin and streptomycin, at 37°C with 5% CO2. A stock
solution of paclitaxel (Alexis, Lausen, Switzerland) was prepared in
DMSO. Vinorelbine (Sigma, Steinheim, Germany) and doxorubicin
(Dakota, Paris, France) were prepared in aqueous solutions.
Transfection Studies
siRNA Bim (signalSilence Bim siRNA I; Cell Signaling Technology,
Beverly, MA) and siRNA Bcl-2 (HP validated siRNA 1027400, target
sequence: AAC CGG GAG ATA GTG ATG AAG; Qiagen, Hilden,
Germany) were transfected into A549 Bcl-2 cells. SiRNA Bcl-2 was
designed and validated to minimize the risk of off-target effects. siRNA
Bim specifically inhibits Bim expression using RNA interference, a
method whereby gene expression can be selectively silenced through
the delivery of double-stranded RNA molecules into the cell. Non-
targeting siRNA [Signalsilence control siRNA (Cell Signaling Tech-
nology) concerning Bim studies and AllStars Negative control siRNA
(Qiagen) for Bcl-2 studies] was used as controls for non–sequence-
specific effects of the transfected siRNA.
A549 wild-type cells (A549 w) were transfected with pcDNA6
plasmid (pcDNA6) or containing BimEL cDNA (pcDNA6-Bim),
kindly given by A. Vazquez [33]. These transfections were achieved
using Lipofectamine 2000 (Invitrogen) according to the protocol
supplied by the manufacturer.
Cytotoxicity Assay
Cells were seeded in 96-well plates to be treated for 48 or 72 hours
with different agents: paclitaxel, vinorelbine, and doxorubicin. Doses
of MTAs used to treat cells in vitro were in the range of plasma con-
centrations measured in the patient [34]. For A549 Bcl-2 cells, we
tested the effect of mdivi-1, a small-molecule mitochondrial divi-
sion inhibitor, at 1 μM with paclitaxel. Growth inhibition was mea-
sured using the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide (MTT) cell proliferation assay. This colorimetric assay allows
the monitoring of cell survival in vitro. Each experiment included
vehicle-treated cells (controls) that proliferate following an exponen-
tial model. For each dose of anticancer drug tested, results were
expressed as percentage of survival cells, according to the following
equation: ODtreated cells × 100/ODcontrol cells.
Animal Studies
All the experimental procedures and animal care complied with
French official guidelines. Female BALB/c nude mice 6 to 8 weeks old
were obtained from Charles River Laboratories (L’Arbresle, France). The
animals were housed in a temperature- and humidity-controlled room
with a 12-hour on-off light cycle and given free access to food and water.
A total of 5 × 106 A549 pUse or A549 Bcl-2 cells were inoculated
subcutaneously into the right dorsal flanks of the nude mice. Exper-
imental treatments were started when tumors reached about 50 mm3
in volume (day 0). Mice were then randomly divided into four groups:
group 1 (A549 pUse–bearing mice, n = 8) and group 2 (A549 Bcl-2–
bearing mice, n = 7) received vehicle solution (control groups); group 3
(A549 pUse–bearing mice, n = 8) and group 4 (A549 Bcl-2–bearing
mice, n = 7) were injected with paclitaxel.
We selected an administration schedule of consecutive daily intra-
venous (i.v.) injections for 5 days for paclitaxel, based on effective
similar schedules previously published [35,36]. Paclitaxel was given
to tumor-bearing mice at a dose of 24 mg/kg/day, slightly less than
50 Enhanced Sensitivity in Bcl-2–Overexpressing Cells Savry et al. Neoplasia Vol. 15, No. 1, 2013
the maximum tolerable dose (28 mg/kg/day) in this schedule. Paclitaxel
was dissolved at 24 mg/ml in ethanol/Cremophor EL (1:1) solution
and stored at 4°C. This stock solution was diluted to 2.4 mg/ml with
saline just before injection. Vehicle solution (ethanol/Cremophor EL/
saline, 1:1:18) was given to control groups. The injections were admin-
istered through the tail vein after intraperitoneal anesthesia with xyla-
zine (10 mg/kg)/ketamine (100 mg/kg). Tumor sizes were measured
twice a week and were determined after caliper measurement of the
largest and perpendicular diameters and the depth. Tumor volumes
were calculated according to the following formula: length × width ×
depth × 0.5236. Mice were allowed to live until their natural death or
were sacrificed when their tumor volume exceeded 2000 mm3. Kaplan-
Meier survival curves were plotted and statistically analyzed.
Mitochondrial Reducing Potential Analysis
To measure the mitochondrial reducing potential, we performed
MTT assays after short-time treatments, as described previously [37].
Briefly, cells were incubated for 6 hours with culture medium contain-
ing both paclitaxel (growing concentrations) and MTT (0.5 mg/ml),
and absorbance was measured at 550 nm.
Mitochondria Isolation and Western Blot Analysis
Whole-cell lysates and mitochondrial pellets were prepared as pre-
viously described [37,38]. Equal amounts of proteins were separated
by sodium dodecyl sulfate–polyacrylamide gel electrophoresis and
electrotransferred onto a nitrocellulose membrane. The membranes
were then probed with antibodies directed against Bcl-2 (Dako, Glostrup,
Denmark), Bim (BD Pharmingen, San Diego, CA), α-tubulin (Sigma),
voltage-dependent anion channel (VDAC; Sigma), or caspase-9
(Abcam, Cambridge, United Kingdom). Blots were then labeled with
peroxidase-conjugated secondary anti-mouse or anti-rabbit antibodies
(Jackson ImmunoResearch, Baltimore, MD). Chemiluminescence im-
aging was performed with the Immobilon Western Chemiluminescent
HRP substrate (Millipore, Billerica, MA) and the G-Box acquisition
system (SynGene, Cambridge, United Kingdom). Signals were then
quantified with the GeneTools analysis software, and mean values of
three independent experiments are indicated in figures.
Flow Cytometry
After paclitaxel treatment for 24 hours, cells were fixed, permea-
bilized, and stained with propidium iodide as described previously
[22]. Fluorescence was measured by flow cytometry (FACScan;
BD Biosciences, San Jose, CA). The results obtained were analyzed
by CellQuest Pro software (BD Biosciences).
Fluorescent Microscopy of the Mitochondrial Network
Cells were treated for 6 hours with 20 nM paclitaxel and then incu-
bated with 25 mg/ml MitoTracker Red CMXRos (Molecular Probes,
Saint Aubin, France) at 37°C for 20 minutes. To inhibit mitochondrial
fission, we incubated cells for 6 hours with mdivi-1 (Sigma) at 1 μmol/l,
alone or simultaneously combined with paclitaxel. Cells were examined
using a Leica DM-IRBE microscope coupled to a digital camera driven
by MetaMorph software (Princeton Instruments, Trenton, NJ). At
least 300 mitochondria were analyzed for each experimental condition,
from three independent experiments.
Reverse Transcription–Polymerase Chain Reaction Analysis
Reverse transcription–polymerase chain reaction (RT-PCR) was
conducted to amplify bim and β2-microglobulin (β2m) transcript.
Total cellular RNA was extracted with the NucleoSpin RNA II Kit in
accordance with the manufacturer’s instructions (Macherey-Nagel,
Hoerdt, France), and 1 μg of total RNA was used for RT with random
primers. The PCR conditions included a denaturing step at 93°C for
4 minutes, followed by 25 (for β2m) and 34 (for bim) cycles of denatur-
ation at 93°C for 30 seconds, annealing at 55°C for 30 seconds, and
elongation at 72°C for 30 seconds. We verified that the amplifications
were in the linear range. Amplified products were separated by electro-
phoresis on a 2% agarose gel. DNA bands were visualized by ethidium
bromide staining, and the image was then digitized. The level of bim
expression was normalized to β2m transcript [relative expression level
(REL)]. The percentages of variation of bim reported in the text were
the mean values of three experiments.
Microarray Analysis
Total cellular RNA was isolated using the RNeasyMini Kit (Qiagen)
according to the manufacturer’s instructions. Total RNA was checked
for quantity, purity, and integrity by capillary electrophoresis using the
Agilent 2100 Bioanalyzer and Agilent RNA Nano 6000 LabChip kits
(Agilent Technologies, Palo Alto, CA). All the RNA samples presented
an RNA integrity number of 10.0. Overall changes in gene expression
were evaluated using the Agilent Two-Color Microarray-Based Gene
Expression Platform using the Whole Human (V2) Gene Expression
microarray 4 × 44K 60-mer oligonucleotide (Agilent Technologies).
Four different RNA resulting from four different cell cultures of
A549 pUse or A549 Bcl-2 were used to perform the hybridization
on the four arrays. Two hundred nanograms of total RNA was used
to prepare labeled cRNA with the Agilent Low Input Quick Amp Label-
ing Kit, Two Colors, according to the manufacturer’s recommendations.
cRNA yield and Cy3 and efficiency of Cy5 incorporation into the cRNA
were determined using a NanoDrop ND-1000 spectrophotometer
(NanoDrop Technologies, Palo Alto, CA). For each sample, a total of
825 ng of cRNA was fragmented using the Agilent Gene Expression
Hybridization Kit, and then Cy3 cRNA from a A549 pUse sample
and Cy5 cRNA from a A549 Bcl-2 sample were hybridized together
on one array. The hybridization was performed in a hybridization oven
(Robbins Scientific, Sunnybrook, CA) at 65°C at 10 rpm for 17 hours.
Slides were scanned using an Agilent DNA microarray scanner at
5-μm resolution and Cy3/Cy5 intensity data were extracted using
Agilent’s Feature Extraction software including quality control based
on internal controls. Transcriptome analysis was performed using Agi-
lent Genespring GX11 Software. Fold changes were calculated and
genes with more than a two-fold difference and P ≤ .05 (Benjamini-
Hochberg false discovery rate (FDR) parametric statistical test) were
selected for detailed analysis pathways.
Reporter Luciferase Assay
A549 pUse and Bcl-2 cells were transiently transfected using
Lipofectamine 2000 (Invitrogen) with Bim-pGL3, corresponding
to bim promoter DNA, connected to the firefly luciferase gene or
with a Renilla control plasmid pGL4 (Promega, Madison, WI) to
normalize the transfection efficiency.
Next, after 24 hours, a passive lysis was performed, and both fire-
fly and Renilla luciferase activities were quantified using the dual
luciferase reporter assay system (Promega) according to the manufac-
turer’s instructions. Luciferase was quantified using a luminometer
(TD-20/20; Turner Designs, Sunnyvale, CA).
The same experiment was performed with a pGL3 mutated on the
two binding sites of FoxO3a, Bim-luc dm.
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Statistical Analysis
Each experiment was performed at least in triplicate. Data were
expressed as means ± SEM. Statistical significance was tested using
Student’s t test for comparisons between means. A significant differ-
ence between two conditions was recorded for P < .05 or P < .01.
Kaplan-Meier survival curves were plotted using GraphPad Prism 4
(GraphPad Software, San Diego, CA) and analyzed using the log-
rank (Mantel-Cox) test.
Results
MTAs Exert Higher Antiproliferative Effects in
Bcl-2–Overexpressing Lung and Breast Carcinoma Cells
We selected three tumor cell lines for their different tissue origins
(lung, breast, and neuroblastoma). From these different cell lines, we
generated various cellular models overexpressing Bcl-2 to investigate
the role of Bcl-2 in the anticancer activity of MTAs. Protein expres-
sion levels were measured in whole cells to verify transfection success
(Figure 1A) and in isolated mitochondria to ensure Bcl-2 functional
localization (Figure 1B for A549; data not shown for MCF-7 and
SHEP). We verified that with no treatment, doubling times of
Bcl-2–overexpressing cells were not modified compared with pUse-
transfected cells (Figure W1).
The impact of Bcl-2 overexpression on MTA activities was first
evaluated with cell proliferation assays in lung carcinoma A549 cells.
Paclitaxel antiproliferative efficacy was doubled in A549 Bcl-2 cells
than in A549 pUse cells, as indicated by 50% inhibition of surviving
fraction (IC50) values (P < .05; Figure 1, C and D). Analysis of cell
cycle distribution was also performed after a 24-hour paclitaxel treat-
ment (Figure W2) and showed that accumulation in the G2/M phase
was higher in A549 Bcl-2 cells than in A549 pUse cells (46.1 ± 6.4%
versus 34.3 ± 3.5%; P < .05). The increase in sensitivity of A549 cells
that overexpress Bcl-2 was similarly measured with vinorelbine treat-
ment (Figure 1C ). Enhanced MTA activity was confirmed in another
clone of A549 Bcl-2 cells (Figure W3, A and B). The higher sen-
sitivity of A549 Bcl-2 cells may be specific to MTAs, because they dis-
play a significant resistance to the DNA-damaging agent doxorubicin
(2.9-fold, P < .05) (Figure 1, C and D). The use of siRNA directed
against Bcl-2 partly reversed A549 Bcl-2 cell sensitivity to paclitaxel
(IC50 = 16 ± 6 nM in siRNA control cells versus 38 ± 5 nM in siRNA
Bcl-2 cells; Figure 2), definitely linking high Bcl-2 levels with higher
treatment efficacy.
We then performed the proliferation assays in breast carcinoma
cells. As shown in Figure 1, C and D, both paclitaxel and vinorelbine
were more active in MCF-7 Bcl-2 cells than in MCF-7 pUse cells (P <
.05). As in A549 cells, the enhanced treatment cytotoxicity may be
specific to MTAs, because doxorubicin efficacy was decreased in Bcl-2
overexpressing MCF-7 cells (two-fold, P < .05; Figure 1, C and D).
In sharp contrast, Bcl-2 overexpression resulted in resistance of
neuroblastoma SHEP cells to both paclitaxel and vinorelbine (P <
.01). These results clearly indicate that the role of Bcl-2 in poten-
tiating MTA efficacy is cell type dependent but is not limited to lung
cancer cells. Furthermore, our preliminary work showed that over-
expression of Bcl-2 did not enhance paclitaxel cytotoxicity in HBL100
non-cancer breast cells (IC50 = 25 nM for both HBL100 pUse and
Bcl2 cells; data not shown).
Bcl-2 Overexpression Enhances In Vivo Lung Cancer
Sensitivity to Paclitaxel
The role of Bcl-2 in the antitumor activity of MTAs was fur-
ther evaluated in vivo, in nude mice bearing human lung carci-
noma cell xenografts. Animals were treated with paclitaxel or vehicle
(control), by i.v. injections for 5 days. As shown in Figure 3A, in
the vehicle-treated cohort, A549 Bcl-2 tumor growth was unchanged
compared with A549 pUse tumor growth (respectively 1323 ±
295 mm3 and 1307 ± 214 mm3 at experiment completion). This
result shows that the increase in Bcl-2 expression level did not enhance
A549 tumor progression.
Interestingly, 56 days after the start of treatment with paclitaxel,
the mean tumor volume was 2.4 times smaller in mice xenografted
with A549 Bcl-2 cells than with A549 pUse cells (P < .05; Figure 3A).
Bcl-2 overexpression also appeared effective in improving treatment
activity in terms of survival benefits: It led to a substantial increase in
Figure 2. SiRNA directed against Bcl-2 partly reversed A549 Bcl-2
cell sensitivity to paclitaxel. (A) Reduced Bcl-2 expression was
verified by Western blot analysis on whole-cell lysates of A549
48 hours after transfection. Tubulin was used as a loading control.
(B) Cytotoxicity of paclitaxel (48-hour treatment) was measured
using an MTT assay.
Figure 1. Overexpression of Bcl-2 in A549 and MCF-7 cells increased their sensitivity to MTAs. (A) Bcl-2 overexpression was verified by
Western blot analysis on whole-cell lysates of A549, MCF-7, and SHEP cells and on mitochondria isolated from A549 cells (B). Tubulin or
VDAC expression was used as a loading control. (C) Cytotoxicity of paclitaxel, vinorelbine, and doxorubicin (72-hour treatment) was
measured using an MTT assay in A549, MCF-7, and SHEP cells. (D) IC50 values were graphically determined from at least three inde-
pendent experiments for each drug and each cell line (*P < .01, †P < .05).
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median survival, from 67 days in the cohorts of A549 pUse animals
to 92 days in A549 Bcl-2 animals (P < .005; Figure 3B ). Taken
together, these in vivo data are consistent with the in vitro results.
They clearly show that Bcl-2 overexpression is able to increase treat-
ment efficacy in lung cancers.
Bim Up-Regulation Is Responsible for the Enhanced Efficacy of
MTAs in Bcl-2–Overexpressing Cells
To understand how Bcl-2 can enhance lung tumor sensitivity to
treatment, we performed cDNA microarrays to identify differentially
expressed genes between A549 Bcl-2 cells and A549 pUse cells
(Figure 4A ). As expected, Bcl-2 gene expression was considerably
increased in A549 Bcl-2 cells (48-fold, P < .05). We then analyzed
the expression of other Bcl-2 family members known to be involved
in MTA-induced apoptosis [39]. Gene expression profiles of most of
them were not significantly modified in Bcl-2–overexpressing cells
(Figure 4A). In particular, there was no variation in mRNA levels
of A1, Mcl-1, and Bcl-XL antiapoptotic proteins. Expression levels
of the proapoptotic actors Bax, Bak, Puma, Noxa, and Bmf were
either not modified or decreased, so they could not be responsible
for the higher sensitivity of A549 Bcl-2 cells to treatment. How-
ever, increase in mRNA levels of both Bad (1.3-fold) and bim
(2.5-fold) was detected in A549 Bcl-2 cells versus A549 pUse cells
(P < .05).
We thus focused our attention on Bim, a proapoptotic member of
the Bcl-2 family, which 1) underwent the highest change in expres-
sion and 2) is able to bind to microtubules and to be released toward
mitochondria by MTAs [24]. The unexpected Bim overexpression
in A549 Bcl-2 cells was first confirmed by RT-PCR (Figure 4B )
and by Western blot (Figure 4C , left panel ). These results were
concomitantly validated in another clone of A549 Bcl-2 cells
(Figure W3C ). In addition, Bim overexpression in A549 Bcl-2 cells
was reversed by Bcl-2 silencing (Figure 4D), confirming that this
process is Bcl-2 dependent. Bim up-regulation was not specific to
lung cancer cells, because similar variations were measured in breast
MCF-7 Bcl-2 cells (data not shown). In sharp contrast, in SHEP
cells overexpressing Bcl-2, in which a classic resistance to MTAs
was observed, no overexpression of Bim was detected, either at
mRNA or protein level (Figure 4, B and C , right panel ). Consider-
ing the response of the three cell types to treatments (see above),
our data strongly suggest that Bim expression level may control cell
sensitivity to treatment.
This hypothesis was supported by the finding that Bim silencing
suppressed the gain in treatment efficacy (Figure 5, A and B). Pac-
litaxel IC50 value was 2.5 times higher in A549 Bcl-2 cells transfected
with Bim siRNA than in control siRNA–transfected ones (P < .05).
The hypothesis was also supported by bim cDNA transfer in A549
wild-type cells (Figure 5C ), which enhanced paclitaxel efficacy (IC50
decreased from 32 ± 6 nM in A549 pcDNA6 cells to 20 ± 1 nM in
A549 pcDNA6-Bim cells, data not shown). The present study thus
shows that Bim up-regulation, mediated by Bcl-2 overexpression in
lung and breast cancer cells, is responsible for the unexpected improved
response to treatment.
The Increase in bim Promoter Transcriptional Activity Is
FoxO Dependent
Increase in bim mRNA levels in Bcl-2–overexpressing cells sug-
gests the establishment of a transcriptional regulation. We examined
this hypothesis using a reporter gene construct containing a firefly
luciferase under the control of the wild-type bim promoter (Bim
pGL3). As shown in Figure 6A, bim promoter transcriptional activity
was increased 2.3 ± 0.2-fold in A549 Bcl-2 cells versus A549 pUse
cells (P < .01).
Bim mRNA expression is mainly regulated by FoxO3a, a member
of the FoxO family of transcription factors. We first studied FoxO3a
localization, because it must reside in the nucleus to bind to its cog-
nate DNA targeting sequences. By confocal microscopy, we showed
that FoxO3a was mainly present in the cytoplasm of A549 pUse
cells, while it partly colocalized with the nucleus in A549 Bcl-2 cells
(Figure 6B). Consistent with this finding, FoxO3a was more active
in A549 Bcl-2 cells, as indicated by the increase in MnSOD mRNA
level, a well-known target of the transcription factor, measured by
DNA microarray (1.8-fold, P < .05, data not shown) and confirmed
by RT-PCR (Figure 6C ). This same target is not activated in SHEP
Bcl-2 cells (Figure 6C ).
Additionally, the DNAmicroarray analysis, confirmed by RT-PCR
(Figure 6C ), revealed that SGK2 mRNA was decreased in A549 Bcl-2
cells compared with A549 pUse cells (3.1-fold, P < .05, data not
shown). Since SGK can inhibit FoxO3a nuclear translocation by
phosphorylation, a reduction in its level may explain FoxO3a activa-
tion in A549 Bcl2 cells.
To further investigate the role of FoxO3a in Bim up-regulation,
we transfected A549 Bcl-2 cells with Bim-pGL3 dm, a double mutant
Bim-LUC reporter construct that contains mutations in the bim1 and
bim2 FoxO sites. In these cells, we recorded a 2.7-fold decrease in
bim promoter transcriptional activity (Figure 6D). Taken together,
Figure 3. Overexpression of Bcl-2 enhances A549 lung cancer sen-
sitivity to paclitaxel in vivo. (A) Tumor volumes in A549 pUse or
A549 Bcl-2 cell–bearing mice receiving i.v. injection of vehicle
(control) or paclitaxel (P < .05). Tumors were measured twice a
week for 56 days after the initial treatment (day 0). (B) Kaplan-
Meier curves showing survival in paclitaxel-treated A549 pUse or
A549 cell–bearing mice compared with controls.
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our results clearly demonstrate that Bim transcriptional regulation,
mediated by Bcl-2 overexpression, is FoxO3a dependent.
Bim-Mediated Increase in Cell Sensitivity to Treatment Is
Linked to Mitochondrial Network Disruption
To decipher the functional consequences of Bim up-regulation in
Bcl-2–overexpressing cells, we first checked that the mitochondrial
membranes were permeabilized, a key step in the MTA mechanism
of action. First, we recorded an increase in the mitochondrial reducing
potential in A549 Bcl-2 cells after a short-time treatment with paclitaxel
(6 hours, P < .05), whereas it did not vary in A549 pUse cells
(Figure W4A). We then observed the release of cytochrome c from
mitochondria after a 24-hour treatment with paclitaxel (Figure W4B).
Lastly, we detected caspase-9 activation, indicated by the cleavage of the
pro-caspase-9 in a dose- and time-dependent manner (Figure W4C ).
Taken together, these assays confirmed that paclitaxel activates the
mitochondrial apoptotic pathway in lung cancer cells that express high
levels of Bim, even though cells also overexpress Bcl-2.
Morphology of mitochondria is crucial for maintaining their func-
tions and depends on the balance between fission and fusion. We thus
investigated the impact of paclitaxel on the mitochondrial network
morphology by fluorescence microscopy. As expected, untreated cells
displayed elongated tubular mitochondria (Figure 7, A and B, left
panels), and paclitaxel disturbed the mitochondrial network fission/
Figure 4. Bim mRNA and protein expression is induced in Bcl-2–overexpressing A549 cells. (A) Differences in gene expression profiles
of Bcl-2 family members in A549 Bcl-2 cells versus A549 pUse cells, using DNA microarray analysis. Protein expression change in the
grayed part of the histogram is less than two-fold. (B) Bim mRNA expression was analyzed by RT-PCR and normalized to β2m transcript
(REL). Western blot analysis of Bim protein was performed in whole-cell lysates from A549, SHEP (C), and A549 Bcl-2 cells transfected
with siRNA Bcl-2 (D). Transfection efficiency was thus verified after 24 hours, when adding drug in experiments. Tubulin expression was
used as a loading control to determine REL.
Figure 5. Bim expression level controls cell sensitivity to paclitaxel.
(A) A549 Bcl-2 cells were transfected with either siRNA control or
siRNA Bim. A549 wild-type cells (A549 w) were transfected with
pcDNA6 or pcDNA6-Bim. Transfection efficiency was verified by
Western blot analysis at 24 hours, when adding drug in experi-
ments. (B) Cytotoxicity of a 48-hour paclitaxel treatment was eval-
uated in A549 Bcl-2 cells transfected with siRNA control and
siRNA Bim (*P < .05).
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fusion balance. Both A549 pUse and SHEP pUse cells displayed
spherical organelles after a short-time treatment (Figure 7, A and B,
right panels). More interestingly, by quantifying cells with a fragmented
mitochondrial network, we revealed a three-fold increase in this process
in A549 Bcl-2 cells compared with A549 pUse cells (P < .05). By con-
trast, paclitaxel-mediated fragmentation of the mitochondrial network
was not enhanced in SHEP Bcl-2 cells (60 ± 4%) compared with SHEP
pUse cells (66 ± 4%).
To further study the mechanisms underlying the mitochondrial
network fragmentation induced by paclitaxel, we evaluated the role
of Drp1, a key actor of mitochondrial fission. The pharmacological
inhibitor of Drp1 (mdivi-1) reduced the quantity of A549 Bcl-2 cells
with punctuated mitochondria from 42 ± 7% to 28 ± 1% (P < .05;
Figure 7, A and C ). Concomitantly, the cytotoxic effect of paclitaxel
(IC70) was decreased 1.7-fold when simultaneously combined with
mdivi-1, indicating that treatment efficacy in A549 Bcl-2 cells was
related to the promotion of mitochondrial fission.
Finally, to determine whether Bcl-2–mediated up-regulation of Bim
could be responsible for mitochondrial fission, we tested the effect of
Bim silencing on this process. After paclitaxel treatment, the propor-
tion of cells that displayed a fragmented mitochondrial network de-
creased from 65 ± 3% in siRNA control cells to 41 ± 5% in bim
siRNA–transfected cells (P < .01; Figure 7D). Thus, Bim silencing
leads to resistance of A549 Bcl-2 cells to paclitaxel by an mdivi-1–like
inhibition of mitochondrial fission. Our results thus highlight Bim in-
volvement in the enhanced sensitivity of Bcl-2–overexpressing cells by
disrupting the mitochondrial network dynamics and functions in lung
cancer cells.
Discussion
Accumulating evidence from preclinical studies and clinical trials sug-
gests that targeted therapies that work by downregulating Bcl-2 may
not be potent in increasing the efficacy of some conventional
chemotherapies. In the present study, we show for the first time the
involvement of Bim in MTA efficacy, supporting interest in BH3-
mimetic strategies to improve treatment of lung cancers and overcome
drug resistance.
The aim of our work was to evaluate response to treatment for
tumors that intrinsically overexpress Bcl-2. The study design, by gene
transfer in tumor cells, enables us to efficiently induce Bcl-2 over-
expression, as observed in many patients, including those bearing
lung cancers [30]. To date, up-regulation of the prosurvival protein
Bcl-2 remains widely considered as a mechanism involved in tumor
cell resistance to MTAs [14,40]. However, in Bcl-2–overexpressing
lung and breast cells, we showed here that paclitaxel and vinorelbine
activities were increased. In the literature, previous in vitro studies
highlighted a role for Bcl-2 in cell sensitivity to MTAs. In particular,
Bcl-2 up-regulation resulted in the enhanced sensitivity of lung
cancer cells to docetaxel [19]. High expression levels of Bcl-2 in
breast and ovarian cancer cells are also liked to a higher sensitivity
to vinca alkaloids and paclitaxel [21,22,31]. Thus, patients with
Bcl-2 positive tumors may be MTA responsive.
Interestingly, Bcl2 protein was detected in metaplasia and increased
with the development of malignancy, while it was expressed in any
normal lung specimens [41]. Hence, we can assume that Bcl-2–
overexpressing tumor cells are more sensitive to MTAs than surround-
ing normal cells, which may help improve patient care.
In the present study, we further validated in vivo this dual role for
Bcl-2 in MTA treatment potency, using mouse models bearing Bcl-2–
overexpressing non–small cell lung xenografts.
Interestingly, we revealed that Bcl-2 overexpression selectively
induced the expression of the mitochondrial proapoptotic Bim, result-
ing in the increased sensitivity of cancer cells to MTAs. In addition,
siRNA directed against Bcl-2 restored the basal expression level of
Bim and the standard response to treatment. This may help to explain
why high expression levels of Bcl-2 can correlate with favorable clinical
outcomes for patients with several types of cancer [42,43].
Figure 6. Bim expression in Bcl-2–overexpressing cells is modulated
by FoxO3a. (A) Luciferase activity was measured in A549 pUse and
A549 Bcl-2 cells. (B) FoxO3a colocalizedwith the nucleus, stainedwith
propidium iodide (PI), in A549 Bcl-2 cells, and remained only cytoplas-
mic in A549 pUse cells (scale bars, 10 μm). (C) RT-PCR analysis of
MnSOD and SGK mRNA expression. (D) Luciferase activity in A549
Bcl-2 cells transfectedwith a FoxO-mutated binding site bim promoter
construct (Bim-luc dm) compared with the wild-type plasmid.
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Bound in an inactive form to microtubules through the dynein light
chain [26], Bim accumulates in mitochondria to trigger membrane
permeabilization. It has been shown to play a major role in paclitaxel
and epothilone-induced cancer cell death [23,24]. This involvement of
signaling associated with disturbances of the microtubule system could
explain why the higher sensitivity of Bcl-2–overexpressing cells may be
specific to MTAs.
How Bcl-2 overexpression in turn causes the increase in bim
mRNA amounts remains unanswered. In 2007, Jorgensen et al.
showed that Bcl-2 and Bim could control each other’s expression in
Figure 7. Paclitaxel efficacy involves a Bim-mediated mitochondrial network fragmentation. (A) Mitochondrial morphology in A549 pUse
and A549 Bcl-2 cells, untreated or treated with paclitaxel IC70 for 6 hours. The right-hand photos are magnifications of a localized zone.
(B) Same experiments in SHEP pUse and Bcl-2 cells. (C) Similar experiments in A549 Bcl-2 cells treated with paclitaxel alone or com-
bined with the Drp1 inhibitor mdivi-1. (D) Same experiments after a 6-hour treatment with paclitaxel in A549 Bcl-2 cells transfected with
the siRNA control or the siRNA directed against Bim. Scale bars, 10 μm.
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T cells [44]. In particular, they described that Bcl-2 overexpression,
through a transgene, raised intracellular amounts of Bim. Up to now,
there has been no evidence of any transcription factor that could
activate Bim in response to Bcl-2. In our study, we propose an expla-
nation for the Bcl-2–governed Bim up-regulation. Many studies have
described the central role played by FoxO3a in Bim transcriptional
regulation, including in paclitaxel-treated cancer cells [27]. We con-
firm here its implication by using a bim promoter plasmid carrying
two mutated FoxO binding sites. Inhibition of SGK has been linked
to a decrease in FoxO3a phosphorylation, which results in its acti-
vation through its relocalization from cytosol to nucleus [28,29]. Our
data support the triggering of such a signaling pathway in Bcl-2–
overexpressing A549 cells, since we recorded a decrease in SGKmRNA
levels, visualized FoxO3a nuclear accumulation, and measured the
up-regulation of its well-known target MnSOD. Furthermore, we
previously showed that Bcl-2 inhibits the transcriptional activity of
p53 [45,46], which could lead to a decrease in SGK expression
[47,48]. In response to Bcl-2 overexpression, we thus hypothesize that
Bim is upregulated as a result of the increase in FoxO3a activity,
allowed by p53 and SGK inhibition. Unlike the A549 cell line, we
can infer that the SGK-FoxO3a pathway is not involved in SHEP cell
line, since neither Bim nor MnSOD is upregulated. When activated in
neuroblastoma cells, FoxO3a is able to trigger a Bim-mediated cell
death [49], and the reason why MTAs failed in inducing this process
remains to be deciphered.
The functional consequences of Bim overexpression in cancer cells
have been well documented. Bim triggers the release of proapoptotic
mediators from mitochondria to cytosol, a key step in the cell death
program [5]. Previous work also suggests that mitochondrial frag-
mentation may be required in this process [6]. In the present study,
Bim silencing prevented mitochondrial fragmentation and reversed
paclitaxel sensitivity in Bcl-2–overexpressing lung cells. The precise
molecular mechanisms leading to drug-mediated mitochondrial frag-
mentation are not fully understood, but there is evidence that this
process can result from actions of Bcl-2 family members on the mito-
chondrial fission/fusion machinery [10,11]. In the present study, we
found that Bim was involved in the paclitaxel-mediated mitochon-
drial network fragmentation. Interestingly, a recent study also showed
that the BH3-mimetic ABT-737 led to a widespread fragmentation of
mitochondria in neurons [50]. Consistent with this finding, treatment
of mouse embryonic fibroblasts with the death domain of Bim induced
mitochondria to undergo fission, by increasing Bcl-xL binding with
Drp1 [51]. We show here that Drp1 inhibition decreased drug efficacy,
supporting a role for mitochondrial fission in inhibiting cancer cell
expansion. Another study in A549 cells confirm this hypothesis by
showing that mitochondrial fission defects contribute to apoptotic
resistance in A549 cells [52].
Lastly, our data strongly suggest that cell sensitivity status is mon-
itored by Bim expression level rather than Bcl-2 expression level. Pre-
liminary unpublished data on several malignant breast cell lines
confirm that cell sensitivity to paclitaxel was correlated with Bim expres-
sion levels. Sensitivity to paclitaxel is greater in high Bim-expressing
cells (SKBR3) than in very low Bim-expressing cells (MDA-MB-231).
If Bcl-2 overexpression does not lead to Bim up-regulation, then a classic
resistance is measured, as in neuroblastoma cells. By contrast, when Bcl-2
overexpression induces Bim up-regulation, as observed in breast and
lung carcinoma cells, then MTA efficacy is enhanced. Our findings
are important in the current context of the development of targeted
therapies directed toward Bcl-2. Several studies have proposed an expla-
nation for the lack of efficacy in combining oblimersen with some con-
ventional chemotherapies. Moulder et al. have argued that oblimersen
may not suppress intratumoral Bcl-2 levels sufficiently to affect chemo-
therapeutic sensitivity [18]. Rudin et al. have suggested that Bcl-2,
although overexpressed, would not be a relevant biomarker [16]. Taken
together, these data prompt new therapeutic approaches [53]. Recent
advances include the discovery of small BH3-mimetic molecules, which
inhibit antiapoptotic Bcl-2 proteins through their binding to the hydro-
phobic groove [25]. In particular, gossypol and ABT-737 have already
shown their efficacy in lung cancer [54,55]. Recently, Oakes et al. have
proved the efficacy of ABT-737 for the treatment of basal-like breast
cancers with both elevated Bcl-2 and Bim levels [56]. Similarly, a recent
study suggests the possibility that the loss of Bim expression in non–
small cell lung cancer might be related to resistance to anticancer drugs
[57]. Thus, targeting or overexpressing BH3-only proteins such as
Bim may be a strategy of choice to improve treatment efficacy and
overcome drug resistance to cancer chemotherapy.
To conclude, by showing for the first time a Bcl-2–governed Bim
induction, we offer an explanation for the favorable higher sensitivity
of Bcl-2–overexpressing cells to MTAs. Our work highlights that
rather than Bcl-2 status alone, Bim expression pattern should be de-
termined to predict cell sensitivity to MTA. It would be interesting
to realize tissue microarray (TMA) studies to help validate this bio-
marker in clinical practice. Considering the growing importance of
Bim function as a mediator of apoptosis, the understanding of its gene
regulation and cellular behavior is now an essential objective.
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Figure W1. Bcl-2 overexpression does not change doubling time
from A549 cell lines. A549 pUse and Bcl-2 cells were incubated at
the same concentrations for 24, 48, 72, and 96 hours, and the
number of cells was determined for each condition.
Figure W2. Paclitaxel-mediated G2/M arrest is enhanced in Bcl-2–
overexpressing lung cancer cells. A549 pUse and Bcl-2 cells
were incubated with 10 nM paclitaxel for 24 hours. Percentages
of G2/M-arrested cells are indicated. Data represent three inde-
pendent experiments.
Figure W3. Effect of Bcl-2 overexpression was not clone depen-
dent. (A) Bcl-2 overexpression with no treatment was verified by
Western blot analysis on whole-cell lysates of A549 Bcl-2 clone 2.
Expression tubulin was used as a loading control to calculate REL.
(B) Cytotoxicity of paclitaxel was measured using an MTT assay.
(C) Bim overexpression was verified by Western blot analysis on
A549 Bcl-2 clone 2 cells.
Figure W4. Paclitaxel promptly disturbed mitochondrial functions
and permeability in Bcl-2–overexpressed A549 cells. (A) Exponen-
tially growing cells were incubated with a range of paclitaxel con-
centrations for 6 hours, and mitochondrial reducing potential was
assessed using an MTT test (*P < .05). (B) Cytochrome c localiza-
tion in the cytosol was viewed by immunofluorescence after pac-
litaxel treatment. (C) Cleavage of pro-caspase-9 after paclitaxel
treatment in A549 Bcl-2 cells.
